Citryll secures €85M Series B Funding to advance NET-Targeting Therapy for Inflammatory Diseases
Oss-based Citryll, a biotech company pioneering therapies for immune-mediated inflammatory diseases, has closed an €85 million Series B funding round.

The best Articles in our Network

Previous
Next